Navigation Links
Pharmacyclics Announces Promising Results From Phase 2 Clinical,Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung,Cancer

nd the product development of our pipeline; the possibility that the FDA refuses to approve our NDA; because our Phase 3 clinical trial known as the SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial failed to meet its primary endpoint, the FDA may require additional data, analysis or studies before the NDA is approved by the FDA; the outcome of any discussions with the FDA; the initiation, timing, design, enrollment and cost of clinical trials; unexpected delays in clinical trials and preparation of materials for submission to the FDA as part of our NDA filing; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2006 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330; or CarolynBumgardner Wang of WeissComm Partners, Inc., +1-415-225-5050, forPharmacyclics, Inc.

Web site: http://www.pharmacyclics.com/http://www.yourcanceryourchoice.com/

Ticker Symbol: (NASDAQ-NMS:PCYC)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:9/2/2014)...  Volcano Corporation (Nasdaq: VOLC ), ... economic outcomes on a global basis by developing ... visualization, physiology diagnostics and therapies, said today that ... Healthcare conference on Tuesday, September 9. ... and chief executive officer, will begin at 11:10 ...
(Date:9/2/2014)... , Sept. 2, 2014  VentiRx Pharmaceuticals, ... to the development and commercialization of novel ... an update on corporate and clinical activities ... for future funding, ongoing clinical trials and ... In corporate news, Chief Executive Officer Robert ...
(Date:9/2/2014)... SEATTLE , Sept. 2, 2014 /PRNewswire/ ... company committed to the development and commercialization ... today announced that the U.S. Food and ... designation to the investigation of motolimod (VTX-2337) ... doxorubicin (PLD) for the treatment of women ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3
... 5, 2011 Reportlinker.com announces that ... available in its catalogue: ... Cosmetic Surgery, Facial Aesthetic and Medical ... http://www.reportlinker.com/p0610527/Emerging-Markets-Chinese-and-Indian-Cosmetic-Surgery-Facial-Aesthetic-and-Medical-Laser-Markets-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply The ...
... 2011 The Board of Directors of MSA (NYSE: ... a Vice President of the company, responsible for Global Product ... of November 1, will assume the role of President of ... (MEZ).  In his new role, Dr. Muschter will become a ...
Cached Medicine Technology:Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 2Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 3Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 4Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 5Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 6Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 7Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 8Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 9Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 10Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 11Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 12Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 13Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 14Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 15Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 16Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 17Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 18MSA Elects Dr. Thomas Muschter to Vice President 2
(Date:9/2/2014)... September 02, 2014 Nanomedicine is ... in diagnosing, treating and/or prevention of diseases and ... treating cardiovascular, neurological, and oncology diseases. , ... pertaining to various nanoparticles, their medical usages, and ... exists considerable scope for research in this domain, ...
(Date:9/2/2014)... On Saturday, September 6, 2014, The Concilio will present ... vida! Get Up! Get Moving!®. This event promotes Hispanic family ... for people of all ages and all sizes. The event, ... held at Kiest Park Recreation Center, 3080 S. Hampton Road, ... “Since 2007, we have partnered with National Alliance for Hispanic ...
(Date:9/2/2014)... Durable Medical Goods manufacture ThermoTek ... and financing company LeaseQ, Inc. to help customers acquire ... late 2012, LeaseQ’s breakthrough finance shopping platform has enabled ... need to run their business. , Said LeaseQ ... the ThermoTek sales team to provide customers faster access ...
(Date:9/2/2014)... September 02, 2014 The American Healthcare ... a Free-Tuition Guarantee for its ICD-10 Medical Coding Bridge ... the highest level of confidence to students who are ... coder, but are faced with the uncertainty brought on ... of ICD-10 until October 1st, 2015. , AHDPG’s Free-Tuition ...
(Date:9/2/2014)... (HealthDay News) -- The quality of Americans, diets has ... between the rich and poor is growing, a new ... evidence to date that the extensive efforts by many ... having some payoff, but it also indicates that these ... a doctoral student in the department of nutrition at ...
Breaking Medicine News(10 mins):Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Technology Manufacturer ThermoTek Announces New Partnership with LeaseQ.com to Help More Customers Acquire Equipment Faster and Cheaper 2Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 2Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 3Health News:Quality of U.S. Diet Improves, Slightly 2
... take cues from hues, study finds, , , THURSDAY, Feb. 5 ... Want to be more creative at work? Paint your office ... analyzed the effect of color on 666 students, 17 ... presented on computer screens set to either a red, blue ...
... of human leukemia has provided critical insight into the genetic ... stem cells. The study, published by Cell Press in the ... , is likely to have a profound impact on the ... , Leukemia stem cells (LSCs) were initially described as rare ...
... Free or Discounted Care , ... Tampa, Fla. (PRWEB) ... medical officer and internal medicine specialist of Florida Veterinary Specialists ... Times." Shaw met with People Magazine to talk about the ...
... Feb. 5 The National Patient Advocate ... the mission of creating avenues of improved patient access ... state and federal levels -- today praised Congress for ... Health Insurance Program, or SCHIP, which will extend health ...
... the next 12,weeks eDiets and ExerciseTV will provide ... personalized fitness plans,using the free video-on-demand (VOD) ... to share their weight loss journey with the,world. ... than 1500 applicants, the four Make Me Over ...
... early detection of disease, A Su Salud revealed high ... participants and provided $55 million in free and low ... /PRNewswire/ -- CVS/pharmacy, the ... of "A Su Salud" (To Your Health) health fairs, ...
Cached Medicine News:Health News:Color Can Affect How People Think and Act 2Health News:Color Can Affect How People Think and Act 3Health News:Leukemia stem cells have more in common with embryonic stem cells than adult stem cells 2Health News:Tampa Bay Veterinarian Featured in People Magazine's Heroes in Hard Times 2Health News:Tampa Bay Veterinarian Featured in People Magazine's Heroes in Hard Times 3Health News:National Patient Advocate Foundation Applauds Congress' and President Obama's Decision to Extend Health Coverage to Four Million Uninsured Children 2Health News:How Much Weight Can They Lose in 90 Days? 2Health News:How Much Weight Can They Lose in 90 Days? 3Health News:CVS/pharmacy Launches 2009 'A Su Salud' Health Fairs Providing Free Health Screenings to the Community 2Health News:CVS/pharmacy Launches 2009 'A Su Salud' Health Fairs Providing Free Health Screenings to the Community 3
... KIMBERLY-CLARK BALLARD Adult TRACH ... in T-Piece, Elbow and Double ... separate from vials; 12 vials ... Offers multiple tracheostomy sizes, French ...
... KIMBERLY-CLARK BALLARD Adult TRACH ... designed and labeled for ... Features an isolated cleaning ... minimize potential for contamination ...
... Maxi-Flo® suction catheters ... or straight. , ... catheter kits are latex-free., ... feature a catheter tip ...
... are available with a single lumen or ... swivel, MDI adapter., ,Trac-Wedge™ device, and ... include a patient label. Dual swivel elbow ... All Portex® Steri-Cath® systems are latex-free. , ...
Medicine Products: